Henkel in Advanced Talks to Acquire Olaplex at $2 Per Share 
Citi Names Eric Farina and Rob Cascarino to Lead Global Infrastructure Financing Group 
Google's TurboQuant Algorithm Sends Memory Chip Stocks Tumbling 
Lynas Rare Earths Signs Vietnam Deal with LS Eco Energy to Boost Magnet Metal Production 
Reflection AI Eyes $25 Billion Valuation in Massive $2.5 Billion Funding Round 
Berkshire Hathaway and Tokio Marine Form Major Strategic Insurance Partnership 
SpaceX IPO Filing Expected This Week as Valuation Could Surpass $75 Billion 
Delivery Hero Sells Taiwan Foodpanda to Grab for $600 Million in Debt-Reduction Push 
Global Flight Cancellations 2026: Middle East Air Travel Chaos Explained 
Nanya Technology Shares Surge 10% After $2.5 Billion Private Placement from Sandisk and Cisco 
Rio Tinto's Resolution Copper Mine: U.S. Smelting Challenges and Global Operations Update 
Golden Dome Missile Defense: Anduril and Palantir Join Forces on Trump's $185B Space Shield 
Finnair Orders 18 Embraer E195-E2 Jets in Landmark Fleet Overhaul 
AWS Bahrain Region Disrupted by Drone Activity Amid Middle East Conflict 
CK Hutchison's Panama Ports Dispute Escalates as Arbitration Claims Surpass $2 Billion 
SLMG Beverages Eyes Price Hikes Amid Rising Packaging Costs and India's Booming Soft Drink Market 
Air Canada Express Crash at LaGuardia: Controller Distracted by Prior Emergency 
SK Biopharmaceutical is eyeing a share of the 4 trillion won US antiepileptic drug market with its cenobamate tablet Xcopri, which treats partial-onset seizures in adults.
The drug, approved by the US Food and Drug Administration (FDA) on November 21 last year, provides an extra needed treatment option for people with seizures.
Xcopri is the first Korean novel drug, researched and developed entirely and independently by a Korean pharma firm, notes SK Biopharmaceutical CEO Cho.
It is a product of Cho's 15-year research and development drive.
According to the US FDA, the safety and efficacy of XCOPRI were established in two studies that enrolled 655 adults, which were randomized, double-blind, and placebo-controlled.
The FDA granted Xcopri's approval to SK Life Science Inc., the US arm of SK Biopharmaceutical.
Thus, SK Life Science will undertake the US distribution of Xcopri.
